Literature DB >> 16480962

Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.

Kenichiro Ogura1, Yuko Ishikawa, Teppei Kaku, Takahito Nishiyama, Tomokazu Ohnuma, Kei Muro, Akira Hiratsuka.   

Abstract

Tamoxifen (TAM), a nonsteroidal antiestrogen, is the most widely used drug for chemotherapy of hormone-dependent breast cancer in women. Trans-4-hydroxy-TAM (trans-4-HO-TAM), one of the TAM metabolites in humans, has been considered to be an active metabolite of TAM because of its higher affinity toward estrogen receptors (ERs) than the parent drug and other side-chain metabolites. In the present study, we found a new potential metabolic pathway of trans-4-HO-TAM and its geometrical isomer, cis-4-HO-TAM, via N-linked glucuronic acid conjugation for excretion in humans. N+-Glucuronides of 4-HO-TAM isomers were isolated along with O-glucuronides from a reaction mixture consisting of trans- or cis-4-HO-TAM and human liver microsomes fortified with UDP-glucuronic acid and identified with their respective synthetic specimens by high performance liquid chromatography-electrospray ionization time-of-flight mass spectrometry. Although N- and O-glucuronidating activities of human liver microsomes toward trans-4-HO-TAM were nearly comparable, O-glucuronidation was predominant for cis-4-HO-TAM conjugation. Only UGT1A4 catalyzed the N-linked glucuronidation of 4-HO-TAM among recombinant human UGT isoforms (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17) expressed in insect cells. In contrast, all UGT isoforms, except for UGT1A3 and UGT1A4, catalyzed O-glucuronidation of 4-HO-TAM. Although O-glucuronidation of 4-HO-TAM greatly decreased binding affinity for human ERs, 4-HO-TAM N+-glucuronide still had binding affinity similar to 4-HO-TAM itself, suggesting that N+-glucuronide might contribute to the biological activity of TAM in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480962     DOI: 10.1016/j.bcp.2006.01.004

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.

Authors:  Ann M Moyer; Vera J Suman; Richard M Weinshilboum; Rajeswari Avula; John L Black; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; James N Ingle; Matthew P Goetz
Journal:  Pharmacogenomics       Date:  2011-10-03       Impact factor: 2.533

Review 3.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 4.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

5.  UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.

Authors:  Nancy Hakooz; Sameh Alzubiedi; Al-Motassem Yousef; Tawfiq Arafat; Rana Dajani; Nidaa Ababneh; Said Ismail
Journal:  Mol Biol Rep       Date:  2012-02-25       Impact factor: 2.316

Review 6.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

Review 7.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Authors:  Natalia Sutiman; Joanne Siok Liu Lim; Thomas E Muerdter; Onkar Singh; Yin Bun Cheung; Raymond Chee Hui Ng; Yoon Sim Yap; Nan Soon Wong; Peter Cher Siang Ang; Rebecca Dent; Werner Schroth; Matthias Schwab; Chiea Chuen Khor; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

9.  A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Authors:  Aleksandra K Greer; Centdrika R Dates; Athena Starlard-Davenport; Vineetha K Edavana; Stacie M Bratton; Ishwori B Dhakal; Moshe Finel; Susan A Kadlubar; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2014-06-10       Impact factor: 3.922

10.  Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

Authors:  Andrea S Blevins-Primeau; Dongxiao Sun; Gang Chen; Arun K Sharma; Carla J Gallagher; Shantu Amin; Philip Lazarus
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.